Trial Profile
Towards the identification of molecular pathways predicting response to vedolizumab (Entyvio®) in Crohn's disease deploying Systems Medicine: the BullsEye Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2018
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 15 Jun 2018 New trial record